<?xml version="1.0" encoding="UTF-8"?>
<p>In fact, by May 11th, 2020 seven vaccines had already entered Phase I clinical trials: (1) encapsulated mRNA encoding protein S (Moderna and NIAID, USA); (2) Adenovirus expressing protein S (Cansino Biologics, China); (3) DCs modified with lentivirus expressing several proteins and CTLs (Shenzen Geno-Immune Medical, China); (4) an APC modified with lentivirus expressing several viral proteins (
 <xref rid="B35" ref-type="bibr">35</xref>); (5) Inno 4800, SARS CoV2 DNA Injection (Innovio, USA); (6) ChAdOx1 vaccine from the Jenner Institute, Oxford University, (UK) which is a genetically modified Adenovirus expressing Coronavirus proteins (
 <xref rid="B39" ref-type="bibr">39</xref>), and is also being tested in a Phase II trial; and finally (7) the whole inactivated coronavirus with Alum by Sinovac, China (
 <xref rid="B40" ref-type="bibr">40</xref>). Furthermore, on July 2nd, 2020 the WHO communicates that there are 18 COVID-19 candidate vaccines in clinical evaluation and more 129 under pre-clinical assays (
 <xref rid="B36" ref-type="bibr">36</xref>).
</p>
